Inclusion Criteria:

- Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

- At least one previous chemotherapy regimen for metastatic breast cancer

- Age 18-75 years

- Measurable disease as defined by the presence of at least one measurable lesion
(except bone metastases, ascites or pleural effusions)

- Performance status (WHO) 0-2

- Adequate liver function(serum bilirubin <1.5 times the upper normal limit, AST and
ALT <2.5 times the upper normal limit in the absence of demonstrable liver
metastases, or <5 times the upper normal limit in the presence of liver metastases),
adequate renal function (serum creatinine <1.5 times the upper normal limit) and bone
marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function

- No radiation of measurable disease (except brain metastases)

- No progressive brain metastases according to clinical or radiological criteria

- No brain metastases without prior radiation therapy

- Written informed consent

Exclusion Criteria:

- Patient unable to take oral medication

- Active infection

- History of significant cardiac disease (unstable angina, congestive heart failure,
myocardial infarction within the previous 6 months, ventricular arrhythmias)

- History of stroke

- Anticoagulation therapy (except of low dose aspirin <325mg)

- Other invasive malignancy except nonmelanoma skin cancer

- Psychiatric illness or social situation that would preclude study compliance

- Pregnant or lactating women